MAD2L2 Recombinant Monoclonal Antibody

說明書

中文名稱：

MAD2L2重組抗體
貨號：

CSB-RA782379A0HU
規(guī)格：

￥1320
圖片：
Western Blot
Positive WB detected in: 293 whole cell lysate
All lanes: Mad2L2 antibody at 1:2000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 25 kDa
Observed band size: 25 kDa

IHC image of CSB-RA782379A0HU diluted at 1:100 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.

Immunofluorescence staining of Hela Cells with CSB-RA782379A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeated by 0.2% TritonX-100, and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品描述：

CSB-RA782379A0HU 重組單克隆抗體靶向MAD2L2蛋白（有絲分裂阻滯缺陷蛋白2同源物2），該蛋白在DNA損傷修復(fù)和細(xì)胞周期調(diào)控中發(fā)揮關(guān)鍵作用，參與維持基因組穩(wěn)定性并通過調(diào)控紡錘體組裝檢查點影響細(xì)胞分裂進程。本抗體經(jīng)多種實驗驗證，適用于ELISA、Western Blot、免疫組化（IHC）及免疫熒光（IF）等檢測方法，其中Western Blot推薦稀釋比為1:500-1:5000，可清晰檢測目標(biāo)蛋白；免疫組化推薦1:50-1:200稀釋，可在組織切片中準(zhǔn)確定位蛋白表達(dá)；免疫熒光建議1:20-1:200稀釋，適用于亞細(xì)胞定位分析。實驗數(shù)據(jù)顯示其具有高特異性和低交叉反應(yīng)性，能夠精準(zhǔn)識別天然及重組MAD2L2蛋白。該產(chǎn)品可廣泛應(yīng)用于DNA修復(fù)機制研究、細(xì)胞周期調(diào)控分析、腫瘤發(fā)生相關(guān)信號通路探索等科研領(lǐng)域，為解析MAD2L2在基因組穩(wěn)定性維持及疾病模型中的功能提供可靠工具。
Uniprot No.：

Q9UI95
基因名：

MAD2L2
別名：

Mitotic spindle assembly checkpoint protein MAD2B (Mitotic arrest deficient 2-like protein 2) (MAD2-like protein 2) (REV7 homolog) (hREV7), MAD2L2, MAD2B REV7
反應(yīng)種屬：

Human
免疫原：

A synthesized peptide derived from human Mad2L2
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

4D8
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:200
IF	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Adapter protein able to interact with different proteins and involved in different biological processes. Mediates the interaction between the error-prone DNA polymerase zeta catalytic subunit REV3L and the inserter polymerase REV1, thereby mediating the second polymerase switching in translesion DNA synthesis. Translesion DNA synthesis releases the replication blockade of replicative polymerases, stalled in presence of DNA lesions. Component of the shieldin complex, which plays an important role in repair of DNA double-stranded breaks (DSBs). During G1 and S phase of the cell cycle, the complex functions downstream of TP53BP1 to promote non-homologous end joining (NHEJ) and suppress DNA end resection. Mediates various NHEJ-dependent processes including immunoglobulin class-switch recombination, and fusion of unprotected telomeres. May also regulate another aspect of cellular response to DNA damage through regulation of the JNK-mediated phosphorylation and activation of the transcriptional activator ELK1. Inhibits the FZR1- and probably CDC20-mediated activation of the anaphase promoting complex APC thereby regulating progression through the cell cycle. Regulates TCF7L2-mediated gene transcription and may play a role in epithelial-mesenchymal transdifferentiation.
基因功能參考文獻(xiàn)：
1. results provide insights into the structure of the Rev1/Polzeta TLS assembly and highlight the function of Rev7 homo- and heterodimerization. PMID: 30111544
2. Skp2, a confirmed APC/C-CDH1 substrate and E-cadherin destroyer, was increased in TGF-beta1-treated proximal tubular epithelial cells, which could be blocked by MAD2B depletion. PMID: 27488450
3. structure-based interaction analyses revealed an unprecedented mechanism involving CAMP's WK motif. Surprisingly, in one of the crystal forms, the MAD2L2-CAMP complex formed a dimeric structure in which the C-terminal region of MAD2L2 was swapped and adopted an immature structure PMID: 28887307
4. REV7 is a previously undescribed FA gene, which we term FANCV PMID: 27500492
5. Knockdown of REV7 inhibited the migration, invasion, and epithelial-mesenchymal transition (EMT) of breast cancer cells. Meanwhile, overexpression of REV7 promoted the migration, invasion, and EMT of breast cancer cells. PMID: 27712588
6. hMAD2 also binds to the hREV7-binding sequence in hREV3, whereas hMAD2 does not bind to a similar sequence in ADAM9 or ELK-1 and hREV7 does not bind to the hMAD2-binding sequence in hMAD1 or hCDC20. PMID: 20088965
7. data establish MAD2L2 as a crucial contributor to the control of DNA repair activity by 53BP1 that promotes NHEJ by inhibiting 5' end resection downstream of RIF1 PMID: 25799990
8. results reveal an unexpected crucial function of REV7 downstream of 53BP1 in coordinating pathological DSB repair pathway choices in BRCA1-deficient cells PMID: 25799992
9. that MAD2B may play an important role in high glucose-mediated podocyte injury of diabetic nephropathy via modulation of Cdh1, cyclin B1, and Skp2 expression PMID: 25651564
10. Rev7 is essential for mutagenesis and S phase progression in UV-irradiated fibroblasts. PMID: 18295554
11. These findings indicate that depletion of REV7 enhances sensitivity to cisplatin treatment in ovarian clear cell carcinoma (CCC), suggesting that REV7 is a candidate molecular target in CCC management. PMID: 24597627
12. MAD2L2 helps to ensure a robustly bistable switch between APC/C(CDC20) and APC/C(CDH1) during the metaphase-to-anaphase transition, thereby contributing to mitotic fidelity. PMID: 24100295
13. REV7 is required for anaphase-promoting complex-dependent ubiquitination and degradation of translesion DNA polymerase REV1. PMID: 23287467
14. MAD2B may mediate Sim2 function during development in CNS and thereby play a critical role in pathophysiological mechanisms in Down syndrome PMID: 22660985
15. analysis of the crystal structure of the ternary complex composed of the C-terminal domain of human REV1, REV7, and a REV3 fragment PMID: 22859296
16. the Rev1 C-terminal domain utilizes independent interaction interfaces to simultaneously bind a fragment of the 'inserter' poleta and Rev7 subunit of the 'extender' polvarsigma, thereby serving as a cassette that may accommodate several polymerases PMID: 22828282
17. ternary complex of the C-terminal domain of human REV1 in complex with REV7 bound to a REV3 fragment has been crystallized. The crystals belonged to space group P3(1)21, with unit-cell parameters a = b = 74.7, c = 124.5 A PMID: 22869133
18. The REV1/Polzeta complex maintains genomic stability by directly participating in DNA double-stranded break repair. PMID: 21926160
19. Data show that MAD2B interacts with CLTA during the G2/M phase of the cell cycle and that depletion of MAD2B leads to a marked increase in the percentage of misaligned chromosomes and a redistribution of CLTA during mitosis. PMID: 21152103
20. The hRev7 is required for TLS past BPDE-induced DNA lesions but that it is not essential for inserting nucleotides opposite such lesions suggest a role for hPolzeta in the extension step of translesion synthesis. PMID: 21143968
21. show the first crystal structure of REV7 in complex with a fragment of REV3 polymerase (residues 1847-1898) and reveal the mechanism underlying REV7-REV3 interaction PMID: 20164194
22. To clarify the structural basis of the interaction between REV7 and REV3, REV7 was crystallized in complex with a REV3 fragment. PMID: 20054135
23. the small GTPase RAN is a novel MAD2B binding protein PMID: 19753112
24. purified human REV1 and REV7 proteins form a heterodimer in solution, which is stable through intensive purification steps. PMID: 12529368
25. Upregulated MAD2L2 expression is associated with colorectal tumors PMID: 17044027
26. Human Rev7 (hRev7)/MAD2B/MAD2L2 is an interaction partner for Elk-1 and hRev7 acts to promote Elk-1 phosphorylation by the c-Jun N-terminal protein kinase (JNK) MAP kinases. PMID: 17296730
27. Chromophobe renal cell carcinoma presented underexpression of MAD1, and MAD2L2. PMID: 17333263
28. Hepatocellular carcinoma-associated gene 2 interacts with MAD2L2. PMID: 17541814
29. Study provides the first evidence for the involvement of MAD2B in TCF4-mediated epithelial-mesenchymal transdifferentiation. PMID: 19443654
顯示更多

收起更多
相關(guān)疾病：

Fanconi anemia, complementation group V (FANCV)
亞細(xì)胞定位：

Nucleus. Cytoplasm, cytoskeleton, spindle. Cytoplasm. Chromosome.
組織特異性：

Ubiquitously expressed.
數(shù)據(jù)庫鏈接：

HGNC: 6764

OMIM: 604094

KEGG: hsa:10459

STRING: 9606.ENSP00000235310

UniGene: Hs.19400

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human